ClinicalTrials.gg
RecruitingNCT07678229BRIDGE-NKUpdated Aug 13, 2026

BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL

A Phase 3 interventional study of GELAD regimen and MEDA regimen in Extranodal NK/T-cell Lymphoma, sponsored by Rong Tao. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Rong Tao · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China — 22 open to participants now, 25 under way, 2 of them phase 3. Lymphoma, Extranodal NK-T-Cell · China.

Planned enrollment
6th of 65
150 · median 40
Started
2026
with 7 others
Phase 3
5 of 73
2 open now
Primary completion
2031-12
later than 22 of 24 live
Registered
70th of 73
by date
Lead sponsor
4 of 73
Rong Tao

Among the 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China, this one is the 6th largest by planned enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2026, is one of 5 in phase 3, reaches primary completion later than 22 of the 24 other live ones, and was the 70th registered.

Lymphoma, Extranodal NK-T-Cell

270 studies on the registry are indexed under Lymphoma, Extranodal NK-T-Cell; 36 are open to participants now.

Browse Lymphoma, Extranodal NK-T-Cell studies →

Open to participants now

22 of the 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Lymphoma, Extranodal NK-T-Cell studies recruiting now, 11 (55%) set no upper age limit and 8 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China, or all of them as a file.
02

Study summary

This is a randomized, open-label, prospective, multicenter phase III superiority study in patients with newly diagnosed stage IV extranodal NK/T-cell lymphoma. The study compares two frontline induction strategies followed by consolidation with autologous hematopoietic stem cell transplantation in patients who achieve a protocol-defined strict complete remission.

Eligible participants will be randomized 1:1 to Arm A or Arm B, stratified by three-level PINK-E risk category. Arm A consists of one cycle of GELAD induction followed by three cycles of MEDA chemotherapy. Participants who achieve strict complete remission after key response assessment will proceed to autologous hematopoietic stem cell transplantation consolidation. Arm B consists of four cycles of LEAP induction with sintilimab, pegaspargase, and anlotinib. Participants who achieve strict complete remission will receive high-dose methotrexate CNS-directed consolidation followed by autologous hematopoietic stem cell transplantation consolidation if eligible.

The primary endpoint is event-free survival within 24 months after randomization. Secondary endpoints include progression-free survival, overall survival, overall response rate, complete remission rate, strict complete remission rate, autologous hematopoietic stem cell transplantation completion rate, cumulative incidence of relapse, grade 3 or higher adverse events, treatment discontinuation, treatment-related mortality, and plasma EBV-DNA clearance dynamics.

Read the detailed description

Extranodal NK/T-cell lymphoma is an aggressive Epstein-Barr virus-associated lymphoma with poor outcomes in advanced-stage disease. High-dose methotrexate-containing asparaginase-based chemotherapy can induce responses but is limited by early toxicity, organ dysfunction, infection risk, and incomplete treatment delivery in patients with high tumor burden. PD-1 antibody-based immunotherapy combinations have shown promising activity and tolerability in advanced-stage disease, but randomized evidence comparing immunotherapy induction with chemotherapy induction in a frontline curative-intent strategy remains lacking.

This study is designed to evaluate whether immunotherapy induction followed by CNS-directed high-dose methotrexate consolidation and autologous hematopoietic stem cell transplantation can improve event-free survival compared with a conventional chemotherapy induction strategy followed by autologous hematopoietic stem cell transplantation. The comparison focuses on the entire treatment strategy, including induction depth, feasibility of subsequent consolidation, and early strategy failure, rather than isolated response to a single regimen.

Strict complete remission is defined as all of the following: complete metabolic remission on PET/CT according to Lugano 2014 criteria, negative plasma EBV-DNA, and negative EBER staining on repeat bone marrow biopsy for participants with baseline bone marrow involvement.

03

Conditions studied

  • Extranodal NK/T-cell Lymphoma

Keywords

  • Extranodal NK/T-cell lymphoma
  • Epstein-Barr virus
  • Sintilimab
  • Pegaspargase
  • Anlotinib
  • Methotrexate
  • Autologous hematopoietic stem cell transplantation
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 70 years at the time of signing .
  • confirmed extranodal NK/T-cell lymphoma according to the current classification criteria, with tumor tissue confirmed to be EBER positive. Central pathology review is recommended.
  • Stage IV disease according to Lugano 2014 staging criteria, with baseline staging including PET/CT and bone marrow evaluation.
  • Previously untreated disease, with no prior systemic anti-lymphoma therapy, radiotherapy, or other anti-tumor treatment for NKTCL.
  • At least one evaluable lesion assessable by PET/CT and/or contrast-enhanced CT/MRI.
  • performance status score of 0 to 3.
  • Adequate hematologic function during screening, defined as ≥1.0 × 10\^9/L, >80 g/L, and count >50 × 10\^9/L.
  • Adequate hepatic and renal function during screening, defined as and aspartate aminotransferase ≤2 × , total ≤2 × upper limit of normal, and ≥60 mL/min.
  • No severe uncontrolled coagulation disorder, and judged by the investigator to be able to receive pegaspargase-containing therapy.
  • Judged by the investigator to have no absolute to key components of the assigned treatment strategy, including irreversible contraindication to high-dose methotrexate, severe organ dysfunction precluding transplant evaluation, or other conditions clearly preventing completion of the protocol-defined strategy.
  • Written informed consent provided by the participant or legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  • Prior systemic anti-lymphoma therapy, radiotherapy, or anti-tumor therapy.
  • Active central nervous system lymphoma involvement, including active brain parenchymal, meningeal, cerebrospinal fluid, or intraocular involvement.
  • Active infection requiring intensive care support, or infection judged by the investigator to be uncontrolled and likely to significantly interfere with protocol treatment.
  • Known history of acute or chronic pancreatitis, or any condition judged by the investigator to be an absolute to pegaspargase.

Fulminant disseminated intravascular coagulation, or severe coagulation disorder judged by the investigator to be uncorrectable in the short term and to substantially increase treatment risk.

  • Severe cardiac, pulmonary, hepatic, renal, or other major organ dysfunction that, in the investigator's judgment, would significantly interfere with protocol treatment.
  • Irreversible contraindication to high-dose methotrexate, including but not limited to marked renal failure, inability to receive standardized hydration, alkalization, leucovorin rescue, or methotrexate clearance monitoring, or any condition judged by the investigator to prevent safe administration of methotrexate within the protocol-defined strategy.
  • Active virus infection, infection, or active uncontrolled virus replication.
  • Uncontrolled severe hypertension, active bleeding, recent major thromboembolic event, or vascular high-risk condition judged by the investigator to preclude safe administration of anlotinib.
  • Pregnant or breastfeeding women, or participants of unwilling to use effective during the study.
  • Any other medical, psychological, social, or compliance-related condition that, in the investigator's judgment, makes the participant unsuitable for this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Arm A: Chemotherapy Induction Followed by Autologous HSCT Consolidation

    Participants randomized to Arm A will receive one 21-day cycle of GELAD induction followed by three 21-day cycles of MEDA chemotherapy. After completion of GELAD ×1 plus MEDA ×3, participants will undergo key response assessment with PET/CT, plasma EBV-DNA testing, and repeat bone marrow biopsy with EBER staining if bone marrow was involved at baseline. Participants who achieve strict complete remission will proceed to autologous hematopoietic stem cell transplantation consolidation if eligible. Participants who do not achieve strict complete remission and require non-protocol anti-tumor therapy will be managed according to the protocol-defined event rules.

    Drug: GELAD regimen · Drug: MEDA regimen · Procedure: Autologous Hematopoietic Stem Cell Transplantation

  • Experimental
    Arm B: Immunotherapy Induction Followed by HD-MTX and Autologous HSCT Consolidation

    Participants randomized to Arm B will receive four 21-day cycles of LEAP induction with sintilimab, pegaspargase, and anlotinib. After completion of LEAP ×4, participants will undergo key response assessment with PET/CT, plasma EBV-DNA testing, and repeat bone marrow biopsy with EBER staining if bone marrow was involved at baseline. Participants who achieve strict complete remission will receive high-dose methotrexate CNS-directed consolidation for up to 3 doses, followed by autologous hematopoietic stem cell transplantation consolidation if eligible.

    Drug: LEAP regimen · Drug: High-dose methotrexate · Procedure: Autologous Hematopoietic Stem Cell Transplantation

Interventions

  • DrugGELAD regimen

    Gemcitabine 1.0 g/m² on day 1, etoposide 60 mg/m² on days 1-3, pegaspargase 2000 IU/m² on day 4, and dexamethasone 40 mg on days 1-4, repeated every 21 days for 1 cycle.

  • DrugMEDA regimen

    Methotrexate 3.0 g/m² on day 1 as a 3-hour intravenous infusion, etoposide 100 mg/m² on days 2-4, dexamethasone 40 mg on days 1-4, and pegaspargase 2500 IU/m² on day 4, repeated every 21 days for 3 cycles.

  • DrugLEAP regimen

    Sintilimab 200 mg intravenously on day 1, pegaspargase 2500 IU/m² on day 1 with a maximum single dose of 3750 IU, and anlotinib 8 mg orally on days 1-14, repeated every 21 days for 4 cycles.

  • DrugMethotrexateStudies of MethotrexateMethotrexate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants who achieve strict complete remission after LEAP induction will receive methotrexate 3.0 g/m² as a 3-hour intravenous infusion every 2 weeks for up to 3 doses, with hydration, urine alkalization, leucovorin rescue, and methotrexate concentration monitoring.

  • ProcedureAutologous Hematopoietic Stem Cell Transplantation

    Participants achieving strict complete remission will undergo autologous hematopoietic stem cell transplantation according to institutional transplant procedures if eligible.

06

What researchers measure

Primary outcomes

  1. Event-Free Survival Within 24 Months

    Event-free survival is defined as the time from the date of randomization to the first occurrence of any of the following events: disease progression; death from any cause; inability to complete the assigned protocol-defined treatment strategy due to severe adverse events, persistent organ toxicity, treatment-related complications, or other unacceptable toxicity; or failure to achieve strict complete remission at the key response assessment followed by initiation of non-protocol anti-tumor therapy. Participants without an EFS event at 24 months after randomization will be administratively censored at 24 months.

    Time frame: From randomization to the first protocol-defined EFS event or administrative censoring at 24 months after randomization

Secondary outcomes

  1. Progression-Free Survival

    Progression-free survival is defined as the time from randomization to documented disease progression, relapse after response, or death from any cause, whichever occurs first. Participants without an event will be censored at the date of the last valid disease assessment.

    Time frame: From randomization to disease progression, relapse, death, or last disease assessment, assessed up to 66 months

  2. Overall Survival

    Overall survival is defined as the time from randomization to death from any cause. Participants who are alive will be censored at the last date they are known to be alive.

    Time frame: From randomization to death or last confirmed survival status, assessed up to 66 months

  3. Percentage of Participants With at Least One Serious Adverse Event

    The percentage of participants who experience at least one serious adverse event, as defined in the study protocol, during the specified assessment period. Each participant will be counted once regardless of the number of serious adverse events experienced. Serious adverse events will be assessed by the investigator for relationship to protocol treatment.

    Time frame: From the first dose of protocol treatment through 30 days after the last protocol treatment, and through Day +90 after autologous HSCT for transplanted participants, assessed up to 12 months.

  4. Percentage of Participants With at Least One Grade 3 or Higher Adverse Event

    The percentage of participants who experience at least one grade 3 or higher adverse event, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Each participant will be counted once according to the highest adverse event grade experienced during the assessment period.

    Time frame: From first dose of protocol treatment through 30 days after the last protocol treatment, and through Day +90 after autologous HSCT for transplanted participants, assessed up to 12 months

  5. Percentage of Participants Who Permanently Discontinue a Key Component of the Assigned Treatment Strategy Due to Adverse Events

    The percentage of participants who permanently discontinue at least one key component of the assigned protocol-defined treatment strategy because of an adverse event, treatment-related toxicity, or treatment-related complication. Each participant will be counted once.

    Time frame: From first dose to permanent discontinuation of assigned protocol treatment, assessed up to 12 months

  6. Strict Complete Remission Rate at Key Response Assessment

    Strict complete remission rate is defined as the proportion of participants who meet all of the following criteria: complete metabolic remission on PET/CT, negative plasma EBV-DNA, and negative EBER staining on repeat bone marrow biopsy among participants with baseline bone marrow involvement.

    Time frame: At key response assessment after assigned induction treatment, approximately 12-20 weeks after randomization

  7. Percentage of Participants With Treatment-Related Mortality

    The percentage of participants who die from an adverse event or complication judged by the investigator to be related to protocol treatment, treatment-related supportive procedures, or autologous hematopoietic stem cell transplantation.

    Time frame: From first dose through 30 days after the last protocol treatment, and through Day +90 after autologous HSCT for transplanted participants, assessed up to 12 months

  8. Percentage of Baseline Plasma EBV-DNA-Positive Participants With Plasma EBV-DNA Clearance at the Key Response Assessment

    The percentage of participants with detectable plasma Epstein-Barr virus DNA at baseline who achieve plasma EBV-DNA clearance at the key response assessment. Plasma EBV-DNA will be measured using quantitative real-time polymerase chain reaction and reported in copies/mL. Plasma EBV-DNA clearance is defined as a decrease from a detectable baseline value to less than 500 copies/mL or below the lower limit of quantification of the assay. The denominator will include baseline plasma EBV-DNA-positive participants with an evaluable plasma EBV-DNA result at the key response assessment.

    Time frame: At the key response assessment after completion of assigned induction treatment, approximately 12 to 20 weeks after randomization.

  9. Overall Response Rate at Key Response Assessment

    Overall response rate is defined as the proportion of participants achieving complete remission or partial remission according to Lugano 2014 criteria at the key response assessment.

    Time frame: At key response assessment after assigned induction treatment, approximately 12-20 weeks after randomization

  10. Percentage of Randomized Participants Who Complete Autologous Hematopoietic Stem Cell Transplantation

    The percentage of all randomized participants who complete autologous hematopoietic stem cell transplantation after achieving protocol-defined strict complete remission and meeting transplant eligibility criteria. The denominator will include all randomized participants in each treatment arm.

    Time frame: From randomization to completion of autologous HSCT, assessed up to 12 months

  11. Cumulative Incidence of Relapse Among Participants Who Achieve Strict Complete Remission

    The cumulative incidence, expressed as a percentage, of first lymphoma relapse among participants who achieve protocol-defined strict complete remission at the key response assessment. Relapse will be assessed according to Lugano 2014 criteria using PET/CT and, where clinically indicated, contrast-enhanced CT or MRI, bone marrow evaluation, and plasma EBV-DNA testing. Death without documented relapse will be treated as a competing event.

    Time frame: From the date of first documented strict complete remission to relapse, death, or the last valid disease assessment, assessed up to 66 months after randomization.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22. PubMed 35732829 ↗
  • Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Espanol de Medula Osea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800. PubMed 25113753 ↗
  • Li D, Liu C, Wan J, Zhang W, Ma Y, Zhu Y, Ma L, Tian S, Ding H, Tao R. Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study. Blood Adv. 2026 Mar 3:bloodadvances.2025018720. doi: 10.1182/bloodadvances.2025018720. Online ahead of print. PubMed 41774854 ↗
  • Zhu Y, Tian S, Xu L, Ma Y, Zhang W, Wang L, Jin L, Liu C, Zhu C, Li Z, Hao S, Zhong H, Ding H, Tao R. GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T-cell lymphoma: a prospective multicentre study. Br J Haematol. 2022 Feb;196(4):939-946. doi: 10.1111/bjh.17960. Epub 2021 Nov 21. PubMed 34806163 ↗
  • Liu C, Ding H, Zhu Q, Liu P, Zhu Y, Wang L, Ma Y, Zhang W, Tian S, Zhang X, Jin L, Liu L, Li Z, Hao S, Tao R. Induction with MEDA regimen and consolidation with Auto-HSCT for stage IV NKTCL patients: A prospective multicenter study. Int J Cancer. 2022 Sep 1;151(5):752-763. doi: 10.1002/ijc.34055. Epub 2022 Jun 9. PubMed 35489026 ↗

Individual participant data

Plan to share: Undecided — IPD sharing is currently undecided. The study team will determine whether de-identified participant-level data can be shared after study completion in accordance with institutional policy, participant consent, and applicable regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2031, 64 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jul 1, 2026
StartActual
Aug 11, 2026
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2031
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07678229
Lead sponsor
Rong Tao
Responsible party
Rong Tao (Department head, professor, Fudan University) — Sponsor-investigator
First posted
Jul 1, 2026
Start date
Aug 11, 2026
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Aug 13, 2026

Study contacts

Rong Tao, MD & PhD
Contact
hkutao@hotmail.com
008621-64175590 ext. 660103
Chuanxu Liu, MD & PhD
Contact
liuchaunxu@shca.or.cn
008621-64175590 ext. 660103
Rong Tao, MD & PhD
study chair · Shanghai Cancer Center
Chuanxu Liu, MD & PhD
principal investigator · Shanghai Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion